100 related articles for article (PubMed ID: 17315195)
1. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma.
Ogino T; Moriai S; Ishida Y; Ishii H; Katayama A; Miyokawa N; Harabuchi Y; Ferrone S
Int J Cancer; 2007 Jun; 120(11):2401-10. PubMed ID: 17315195
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
3. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.
Ogino T; Bandoh N; Hayashi T; Miyokawa N; Harabuchi Y; Ferrone S
Clin Cancer Res; 2003 Sep; 9(11):4043-51. PubMed ID: 14519625
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma.
Shao JY; Ernberg I; Biberfeld P; Heiden T; Zeng YX; Hu LF
Anticancer Res; 2004; 24(4):2309-18. PubMed ID: 15330177
[TBL] [Abstract][Full Text] [Related]
5. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.
Ogino T; Shigyo H; Ishii H; Katayama A; Miyokawa N; Harabuchi Y; Ferrone S
Cancer Res; 2006 Sep; 66(18):9281-9. PubMed ID: 16982773
[TBL] [Abstract][Full Text] [Related]
6. Beta 2-microglobulin and HLA-DR expression in relation to the presence of Epstein-Barr virus in nasopharyngeal carcinomas.
Kouvidou C; Rontogianni D; Tzardi M; Datseris G; Panayiotides I; Darivianaki K; Karidi E; Delides G; Kanavaros P
Pathobiology; 1995; 63(6):320-7. PubMed ID: 8738471
[TBL] [Abstract][Full Text] [Related]
7. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
[TBL] [Abstract][Full Text] [Related]
8. Detection of Epstein-Barr virus in esophageal squamous cell carcinoma in Taiwan.
Wang LS; Chow KC; Wu YC; Li WY; Huang MH
Am J Gastroenterol; 1999 Oct; 94(10):2834-9. PubMed ID: 10520830
[TBL] [Abstract][Full Text] [Related]
9. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
[TBL] [Abstract][Full Text] [Related]
10. [The expression of HLA, Epstein-Barr virus nuclear antigen and the infiltration of T lymphocyte subsets in nasopharyngeal biopsy tissues].
Chen X; Cai Y; Sun N
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1994; 29(1):6-9. PubMed ID: 8031607
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
13. Constitutive expression of HLA class II antigens on EBV positive malignant cells from nasopharyngeal carcinoma: possible involvement in T cell infiltration.
Busson P; Braham K; Clausse B; Tursz T
Cancer Detect Prev; 1988; 12(1-6):363-8. PubMed ID: 2846171
[TBL] [Abstract][Full Text] [Related]
14. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
15. CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection.
Ohshima K; Suzumiya J; Sugihara M; Nagafuchi S; Ohga S; Kikuchi M
Pathol Int; 1999 Jan; 49(1):9-13. PubMed ID: 10227719
[TBL] [Abstract][Full Text] [Related]
16. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma.
Chao TY; Chow KC; Chang JY; Wang CC; Tsao TY; Harn HJ; Chi KH
Cancer; 1996 Jul; 78(1):24-9. PubMed ID: 8646721
[TBL] [Abstract][Full Text] [Related]
17. Association between EBNA2 and LMP1 subtypes of Epstein-Barr virus and nasopharyngeal carcinoma in Thais.
Tiwawech D; Srivatanakul P; Karalak A; Ishida T
J Clin Virol; 2008 May; 42(1):1-6. PubMed ID: 18180201
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
19. The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.
Tse KP; Wu CS; Hsueh C; Chang KP; Hao SP; Chang YS; Tsang NM
Anticancer Res; 2012 Apr; 32(4):1299-307. PubMed ID: 22493362
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
